The week in pharma: action, reaction and insight – week to October 24
By Barbara Obstoj-Cardwell
Among last week’s significant news, US biotech Veridian Therapeutics announced it has entered into a royalty financing agreement and updated progress on its veligrotug and VRDN-003. Belgian drugmaker Galapagos announced that, having failed to get any significant bids for its cell therapy business it will wind these operations down. On the M&A front, Alkermes revealed a potentially $2.1 billion takeover bid for fellow Ireland based Avadel and its already approved Lumryz treatment for excessive sleepiness. Also of note, Tango Therapeutics released mixed early data on its cancer candidate vopimetostat.
Viridian royalty deal provides further validation & launch funding
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze